David Bragin-Sanchez, MD
Advanced Heart Failure and Transplant Cardiology · Spokane, WANPI 1457364770
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $71,023 of the $83,036 with a category attached, or 85.5%. Johnson & Johnson accounts for 64.4% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2019 at $41,485 and has fallen 62.7% since, to $15,469 in 2025. Among advanced heart failure and transplant cardiology clinicians in WA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 242 payments — averaging $343.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$53K
- Bridgebio Pharma, Inc.$15K
- Novartis$10K
- Abbott$2K
- Actelion Pharmaceuticals US, Inc.$750
- AstraZeneca$533
- plus $572 from 10 others
What the payments were for
- Consulting fees$3000%
- Speaking & faculty fees$71,02386%
- Travel & lodging$6,0907%
- Food & beverage$5,2246%
- Education$3990%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 77 | $53,494 |
| Bridgebio Pharma, Inc. | 11 | $15,224 |
| Novartis | 25 | $10,370 |
| Abbott | 35 | $2,092 |
| Actelion Pharmaceuticals US, Inc. | 51 | $750 |
| AstraZeneca | 16 | $533 |
| Boehringer Ingelheim | 7 | $127 |
| Merck | 6 | $118 |
| Pfizer | 4 | $81 |
| Boston Scientific | 1 | $70 |
| Alnylam Pharmaceuticals Inc. | 3 | $69 |
| Lexicon Pharmaceuticals, Inc. | 2 | $46 |
| Medtronic | 1 | $16 |
| Bayer | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Amgen | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$52,369
- Attruby$15,190
- ENTRESTO$10,035
- CARDIOMEMS$1,288
- LEQVIO$135
- CardioMEMS HF System$116
How this compares
$83,036 in reported general payments places this provider in the 90th percentile of 20 advanced heart failure and transplant cardiology providers in Washington.
See all advanced heart failure and transplant cardiology providers in Washington →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 95 | $2,478,351 |
| OpsumitMacitentan | 49 | $621,292 |
| EntrestoSacubitril/Valsartan | 281 | $371,120 |
| VyndaqelTafamidis Meglumine | 13 | $295,058 |
| EliquisApixaban | 199 | $239,934 |
| FarxigaDapagliflozin Propanediol | 199 | $206,220 |
| JardianceEmpagliflozin | 157 | $170,597 |
| AdempasRiociguat | 11 | $151,997 |
| XareltoRivaroxaban | 116 | $131,183 |
| Tadalafil | 37 | $21,588 |
| Eplerenone | 140 | $14,640 |
| Metoprolol Succinate | 404 | $6,450 |
| Torsemide | 198 | $3,898 |
| Candesartan Cilexetil | 94 | $3,879 |
| VascepaIcosapent Ethyl | 12 | $3,702 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Vyndaqel, Eliquis | $81 | $3,013,343307 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $750 | $621,29249 claims |
| NovartisEntresto | $10,370 | $371,120281 claims |
| AstraZenecaFarxiga | $533 | $206,220199 claims |
| Boehringer IngelheimJardiance | $127 | $170,597157 claims |
| BayerAdempas | $16 | $151,99711 claims |
| Johnson & JohnsonXarelto | $53,494 | $131,183116 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 20 advanced heart failure and transplant cardiology providers in Washington.
Other advanced heart failure and transplant cardiology in Spokane
- Deirdre MooneySpokane$26K
- James MuddSpokane$6K
- Robert ScottSpokane$4K
- Wayne LevySeattle$275K
- David ZhangTacoma$35K
- John MignoneSeattle$19K
- Preethi PirlamarlaSeattle$14K
- Salpy PamboukianSeattle$5K
- Pulla ReddySilverdale$3K
- James ZhangSeattle$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.